Thalidomide, the notorious drug which caused horrendous birth defects in the 1950s and 1960s, is close to making a comeback as an anticancer drug. Drug firm Celgene of Warren, New Jersey, has applied to European drug authorities for permission to sell thalidomide to treat multiple myeloma, a fatal cancer of the bone marrow. In clinical trials the drug performed well against the disease. It will take Europe seven months or more to reach a verdict on the drug, which will not be prescribed to pregnant women or those considering having children.
To continue reading, today with our introductory offers
Advertisement
More from New Scientist
Explore the latest news, articles and features
Popular articles
Trending New Scientist articles
1
Where, when and how to watch the 2026 solar eclipse
2
The race to understand how and when Thwaites glacier will collapse
3
Babies are born with the neural foundations for maths
4
The most detailed survey of the universe ever conducted starts now
5
Humans sleep the least of all apes – is it the secret to our success?
6
We’ve uncovered a master gene that switches on human development
7
The best sci-fi novel in 2026 so far – plus 6 other great reads
8
The world's fastest spider tops 3.5 metres per second
9
Remote-controlled cockroach swarm can now breathe underwater
10
Our verdict on The Selfish Gene: An unpopular piece of popular science
